Global Patent Landscape of Benign Prostatic Hyperplasia Drugs

Liu, Kunmeng; Yang, Jing; Deng, Jian; Fan, Xiaohui; Hu, Yuanjia

doi:10.1016/j.urology.2022.03.008

Cited by 1 publication

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the utilization of a solitary plant extract for the treatment of BPH necessitates a higher dosage, which may impose a greater strain on the liver and kidney functions [ 29 ]. Furthermore, monotherapy typically targets a singular aspect, and prolonged usage may result in the development of drug resistance [ 30 ]. The implementation of combined therapy presents a compelling strategy for managing chronic ailments.…”

Section: Introductionmentioning

confidence: 99%

“…The implementation of combined therapy presents a compelling strategy for managing chronic ailments. As assessed using the International Prostate Symptom Score, combination therapy has demonstrated an enhanced likelihood of better recovery and response rates, while also mitigating drug resistance in patients with long-standing chronic conditions [ 30 ]. Therefore, this study aims to evaluate the potential synergistic effects of co-administering LY and CUR in mitigating the development of BPH in rats, while also gaining insight into the multi-target mechanism underlying this combined therapeutic approach.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combination of Lycopene and Curcumin Synergistically Alleviates Testosterone-Propionate-Induced Benign Prostatic Hyperplasia in Sprague Dawley Rats via Modulating Inflammation and Proliferation

Wang

et al. 2023

Molecules

View full text Add to dashboard Cite

Background: Benign prostatic hyperplasia (BPH) is a progressive urological disease occurring in middle-aged and elderly men, which can be characterized by the non-malignant overgrowth of stromal and epithelial cells in the transition zone of the prostate. Previous studies have demonstrated that lycopene can inhibit proliferation, while curcumin can strongly inhibit inflammation. This study aims to determine the inhibitory effect of the combination of lycopene and curcumin on BPH. Method: To induce BPH models in vitro and in vivo, the BPH-1 cell line and Sprague Dawley (SD) rats were used, respectively. Rats were divided into six groups and treated daily with a vehicle, lycopene (12.5 mg/kg), curcumin (2.4 mg/kg), a combination of lycopene and curcumin (12.5 mg/kg + 2.4 mg/kg) or finasteride (5 mg/kg). Histologic sections were examined via hematoxylin and eosin (H&E) staining and immunohistochemistry. Hormone and inflammatory indicators were detected via ELISA. Network pharmacology analysis was used to fully predict the therapeutic mechanism of the combination of lycopene and curcumin on BPH. Results: Combination treatment significantly attenuated prostate hyperplasia, alleviated BPH pathological features and decreased the expression of Ki-67 in rats. The upregulation of the expression of testosterone, dihydrotestosterone (DHT), 5α-reductase, estradiol (E2) and prostate-specific antigen (PSA) in BPH rats was significantly blocked by the combination treatment. The expression levels of inflammatory factors including interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α were strongly inhibited by the combination treatment. From the network pharmacology analysis, it was found that the main targets for inhibiting BPH are AKT1, TNF, EGFR, STAT3 and PTGS2, which are enriched in pathways in cancer. Conclusion: The lycopene and curcumin combination is a potential and more effective agent to prevent or treat BPH.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%